Related Experiment Video
Updated: Jun 25, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site
Suzanne M Jansen1, Laura S Sleumer, Ester Damen
1Department of Cell Biology, Faculty of Science, Radboud University Nijmegen, Heijendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Abstract:
Poor downregulation of ErbB receptors is associated with enhanced downstream signaling and tumorigenesis. It has been suggested that poor downregulation of ErbB-2, -3 and -4 receptors when compared to ErbB1 is due to decreased recruitment of Cbl E3 ligase proteins. However, a highly conserved Cbl binding site is not only present in ErbB1/EGFR (FLQRpY(1045)SSDP), but also in ErbB2 (PLQRpY(1091)SEDP) and ErbB4 (STQRpY(1103)SADP). We therefore replaced the ErbB1 Cbl binding site by that of ErbB2 and ErbB4. Whereas retrovirally infected NIH3T3 cells containing the EGFR Y1045F mutation showed dramatically impaired Cbl recruitment, EGFR ubiquitination and delayed EGFR degradation, replacement of the EGFR Cbl binding site by that of ErbB2 or ErbB4 did not affect Cbl recruitment, receptor-ubiquitination, -degradation, -downregulation or ligand degradation. We conclude that poor downregulation of ErbB2 and ErbB4 receptors is not due to sequence variations in the Cbl binding site of these receptors.
Insights
Poor downregulation of ErbB2 and ErbB4 receptors is not caused by variations in their Cbl binding sites. This finding challenges previous hypotheses linking Cbl E3 ligase recruitment to ErbB receptor downregulation and tumorigenesis.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- Poor downregulation of ErbB receptors, particularly ErbB-2, -3, and -4 compared to ErbB1, is linked to increased downstream signaling and cancer development.
- Previous research suggested that reduced Cbl E3 ligase protein recruitment contributes to the impaired downregulation of ErbB-2, -3, and -4 receptors.
Purpose of the Study:
- To investigate whether sequence variations in the Cbl binding site of ErbB2 and ErbB4 receptors contribute to their poor downregulation compared to ErbB1/EGFR.
- To determine if replacing the ErbB1 Cbl binding site with those from ErbB2 or ErbB4 affects Cbl recruitment, ubiquitination, and degradation.
Main Methods:
- Utilized retroviral infection to introduce modified EGFR constructs into NIH3T3 cells.
- Replaced the native Cbl binding site in EGFR (ErbB1) with the corresponding sequences from ErbB2 and ErbB4.
- Assessed Cbl recruitment, receptor ubiquitination, receptor degradation, and ligand degradation following receptor stimulation.
Main Results:
- A mutation in the EGFR Cbl binding site (Y1045F) significantly impaired Cbl recruitment, EGFR ubiquitination, and delayed EGFR degradation, confirming the site's importance.
- Replacing the EGFR Cbl binding site with sequences from ErbB2 or ErbB4 did not alter Cbl recruitment, receptor ubiquitination, or receptor degradation.
- Downstream signaling and ligand degradation remained unaffected by the Cbl binding site modifications in EGFR.
Conclusions:
- The sequence variations within the Cbl binding site of ErbB2 and ErbB4 receptors are not the cause of their poor downregulation.
- The findings suggest that other mechanisms, beyond Cbl binding site differences, are responsible for the differential downregulation of ErbB receptors.
- This research refutes a key hypothesis regarding the role of Cbl E3 ligase recruitment in ErbB receptor downregulation and tumorigenesis.
More Related Videos
06:45Dissecting Multi-protein Signaling Complexes by Bimolecular Complementation Affinity Purification (BiCAP)
Published on: June 15, 2018
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Mitogens and the Cell Cycle
Receptor Tyrosine Kinases
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...